PREPRINT (not peer reviewed)

Evaluating the Risk of Psilocybin for the Treatment of Bipolar Depression: A Review of the Research Literature and Published Case Studies

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: medRxiv
Date: 2021-04-07
Source: medRxiv
DOI: 10.1101/2021.04.02.21254838
PubMed: Unavailable

Authors

Gard DE Pleet MM Bradley ER Penn A Gallenstein ML Riley LS DellaCrosse M Garfinkle E Michalak EE Woolley JD.

Watch author

Derived topics and classifications

psilocybin Depression Clinical Trial Review Article Safety Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERSInternational Journal of Innovative Technologies in Social Science · 2026-01-22 MedCheck: Psilocybin for Depression, LSD for Anxiety, Donanemab, LSD, and MorePsychiatric News · 2024-04-23 From Trials to Clinics: Considerations for Implementing Psychedelic-Assisted Therapy Into Clinical PracticePharmacology Research & Perspectives · 2026-05-10 Psychedelics’ Use as Medicine Hits Significant RoadblockPsychiatric News · 2024-06-12 Med Check: Psilocybin for OCD, Nuplazid Vote, and MorePsychiatric News · 2022-08-01 G33 Psychedelic drugs for the treatment of chronic pain: is ketamine included?Ask the expert - Psychedelic substances · 2024-08-31 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility.Frontiers in neuroscience · 2026-01-01